Locate Bio Ltd is an innovative orthobiologics company based in the UK. In 2020, the company licensed three patented technologies from Royal College of Surgeons in Ireland (RCSI) for the regeneration of bone and cartilage tissues and the treatment of osteomyelitis. Two of the three RSCI-developed products based on this IP have been granted FDA breakthrough device designation and the in-licensing of this high value IP from RCSI significantly added to the company’s orthobiologics portfolio and investment proposition. The company recently closed a Series A funding round of £10m.
The Innovation Office at RCSI was critical in the development and protection of the IP. It also supported the successful licensing of the IP to Locate Bio and negotiation of terms. Locate Bio plans to continue its collaboration with RCSI and invest in joint R&D opportunities. The company is also investigating manufacturing sites in Ireland.
• ENTERPRISE IRELAND - COMMERCIALISATION FUND
"In-licensing these high-quality complementary, late-stage assets from RCSI has significantly accelerated Locate Bio’s growth trajectory. The end-to-end process of licensing, technology transfer and continued product development has always been very well supported by the RCSI Innovation Team. We have been thoroughly impressed with RCSI’s scientific rigor and innovation and we look forward to continuing to collaborate as we advance our products towards market approval." - John Von Benecke, CEO Locate Bio
Find out more about working with third-level research